Retatrutide and Sleep Apnea: What the TRIUMPH Data May Show

Sleep Apnea as a Target Indication

Obstructive sleep apnea (OSA) is one of the three indications Eli Lilly plans to include in its initial regulatory filing for retatrutide, alongside chronic weight management and osteoarthritis of the knee. This strategic decision reflects both the strong clinical relationship between obesity and OSA and the regulatory precedent established by tirzepatide’s approval for moderate-to-severe OSA under the brand name Zepbound.

No retatrutide-specific OSA data have been published as of April 2026. However, the design of the TRIUMPH-2 trial, the mechanistic basis for weight-loss-driven OSA improvement, and the tirzepatide experience collectively provide a framework for understanding what retatrutide may offer patients with obesity-related sleep apnea.

The Obesity-OSA Connection

The relationship between obesity and obstructive sleep apnea is well established. Excess body weight — particularly fat deposition around the neck, pharynx, and upper airway — directly contributes to airway collapse during sleep. The mechanisms are both structural and functional:

Pharyngeal fat deposition. Increased fat tissue around the upper airway narrows the pharyngeal lumen and increases collapsibility during sleep. This is the most direct mechanism by which obesity causes OSA, and it is directly reversible with weight loss.

Reduced lung volumes. Abdominal obesity reduces functional residual capacity and expiratory reserve volume, which decreases the caudal traction on the upper airway. This reduction in tracheal tug makes the pharynx more prone to collapse.

Systemic inflammation. Obesity produces chronic low-grade inflammation that can contribute to upper airway edema and impaired neuromuscular control of the pharyngeal muscles.

Central drive effects. Leptin resistance and other obesity-related hormonal changes can alter the central respiratory drive, potentially contributing to both obstructive and central apnea events.

Given these mechanisms, significant weight loss consistently improves OSA severity. The magnitude of improvement is generally proportional to the degree of weight loss, which positions retatrutide — with its record-setting weight reduction — as a potentially potent intervention for obesity-related OSA.

The Tirzepatide Precedent: Zepbound for OSA

In late 2024, the FDA approved tirzepatide (Zepbound) for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity. This approval was based on the SURMOUNT-OSA trial program, which demonstrated significant improvements in the apnea-hypopnea index (AHI), the primary measure of OSA severity.

Key findings from the tirzepatide OSA trials included:

• Significant reductions in AHI compared to placebo, with approximately 50% or greater reduction in many participants
• Improvements correlated with degree of weight loss
• Reduction in oxygen desaturation events during sleep
• Improvements in patient-reported sleep quality and daytime sleepiness

The tirzepatide OSA approval established that GLP-1 receptor agonist-mediated weight loss can produce clinically meaningful improvements in OSA — improvements sufficient to meet regulatory standards for a labeled indication. This precedent is directly relevant to retatrutide’s development path.

TRIUMPH-2: Retatrutide’s OSA Program

The TRIUMPH-2 trial includes OSA-related endpoints nested within the broader weight management study. Approximately 1,000 participants are enrolled, with an expected completion date in mid-2026. The trial evaluates retatrutide at 4 mg, 9 mg, and 12 mg versus placebo.

While the specific OSA endpoints and inclusion criteria for the OSA subset have not been fully disclosed in public registrations, Lilly’s Q4 2025 earnings call confirmed that retatrutide’s initial regulatory filing will include OSA as a proposed indication. This means the TRIUMPH-2 data must be sufficient to support an OSA label claim — requiring demonstrable, statistically significant improvement in AHI or equivalent polysomnographic measures.

The TRIUMPH-2 results are expected in the first half of 2026 and will provide the first direct evidence of retatrutide’s effect on OSA severity.

Why Retatrutide Could Outperform Tirzepatide in OSA

The hypothesis that retatrutide may produce greater OSA improvement than tirzepatide rests primarily on the magnitude of weight loss difference between the two drugs.

Greater weight loss. Retatrutide’s Phase 3 weight loss of -28.7% at 12 mg (TRIUMPH-4, 68 weeks) exceeds tirzepatide’s maximum Phase 3 weight loss of approximately -22.5% (SURMOUNT-1, 72 weeks). Since OSA improvement is strongly correlated with weight reduction, the additional 6 percentage points of weight loss could translate to proportionally greater AHI reduction.

Glucagon-mediated effects. Retatrutide’s glucagon receptor agonism produces effects beyond weight loss — including reductions in visceral fat and hepatic fat that may contribute to reduced central adiposity. Since neck and truncal fat distribution is particularly relevant to OSA pathophysiology, preferential reduction in these fat depots could amplify the airway benefits beyond what total weight loss alone would predict.

Systemic inflammation reduction. Retatrutide’s Phase 2 and Phase 3 data have shown significant reductions in high-sensitivity C-reactive protein (hsCRP), a marker of systemic inflammation. Reduced inflammatory burden could improve upper airway edema and neuromuscular function independently of weight loss.

These advantages are plausible but remain unconfirmed. Cross-trial comparisons are inherently limited by differences in patient populations, trial designs, and measurement protocols. Direct evidence from TRIUMPH-2 will be necessary to determine whether retatrutide’s theoretical advantages translate to clinically superior OSA outcomes.

What the Data Could Look Like

Based on the tirzepatide precedent and retatrutide’s greater weight loss, several outcomes are plausible when the TRIUMPH-2 OSA data are reported:

• AHI reductions potentially exceeding those seen with tirzepatide, possibly reaching 55-65% mean reduction at the 12 mg dose
• A meaningful proportion of patients achieving AHI below the diagnostic threshold for moderate OSA (AHI less than 15 events per hour)
• Improvements in nocturnal oxygen saturation, sleep architecture, and daytime sleepiness scores
• Dose-dependent effects, with the 12 mg dose likely showing the greatest OSA benefit

These projections are extrapolations, not predictions. The actual data may differ based on the specific patient population enrolled, baseline OSA severity, concurrent CPAP use, and other design factors.

CPAP and Pharmacotherapy: Complementary Approaches

It is important to note that retatrutide, like tirzepatide, is not positioned to replace continuous positive airway pressure (CPAP) therapy. CPAP remains the standard of care for moderate-to-severe OSA and provides immediate, mechanical relief of airway obstruction during sleep.

Pharmacotherapy-induced weight loss addresses the underlying cause of obesity-related OSA rather than the immediate symptom. In clinical practice, the two approaches are likely to be complementary: pharmacotherapy reduces the severity of the underlying condition while CPAP provides acute symptomatic relief. As weight loss progresses, some patients may be able to reduce CPAP pressure settings or, in cases of significant weight reduction, potentially discontinue CPAP under medical supervision.

The tirzepatide OSA approval did not replace CPAP guidelines, and retatrutide’s anticipated indication would similarly be positioned as an adjunctive or causative treatment rather than a CPAP replacement.

Frequently Asked Questions

Can retatrutide cure sleep apnea?

Retatrutide has not been studied specifically for OSA outcomes as of April 2026. Based on class-level evidence, significant weight loss can substantially improve or even resolve obesity-related OSA in some patients, but this depends on baseline severity, the degree of weight loss achieved, and individual anatomy. OSA often has anatomical and neurological components that persist independent of weight, so complete resolution is not guaranteed even with substantial weight reduction.

How does retatrutide compare to CPAP for sleep apnea?

These are fundamentally different interventions. CPAP mechanically splints the airway open during sleep and provides immediate symptom relief. Retatrutide would address the underlying obesity contributing to airway collapse through sustained weight loss. The two approaches are complementary rather than competitive — CPAP provides acute benefit while pharmacotherapy-induced weight loss addresses the root cause over time.

When will retatrutide OSA data be available?

The TRIUMPH-2 trial, which includes OSA endpoints, has an expected completion date in mid-2026. Topline results could be reported shortly after. Eli Lilly has stated that OSA will be included in the initial regulatory filing for retatrutide, confirming that sufficient OSA data are expected from the TRIUMPH program.

Would I still need a sleep study while taking retatrutide?

Yes. Polysomnography (a sleep study) is the standard diagnostic test for OSA and would be necessary both to establish the diagnosis and to monitor response to any treatment. Even if retatrutide produces significant weight loss, objective sleep study data would be needed to determine whether OSA severity has improved sufficiently to modify other treatments such as CPAP settings.

Is retatrutide better than tirzepatide for sleep apnea?

This cannot be determined from currently available data. Retatrutide produces greater weight loss than tirzepatide in Phase 3 trials (-28.7% vs approximately -22.5%), and since OSA improvement correlates with weight loss magnitude, retatrutide may produce greater AHI reduction. However, no head-to-head OSA comparison has been conducted, and the TRIUMPH-2 OSA results have not yet been reported. Direct evidence will be needed to make this comparison.